Core Viewpoint - The company announced a cash dividend distribution of CNY 0.12 per share for the first half of 2025, totaling CNY 12,986,400 [2][4]. Distribution Plan - The profit distribution plan was authorized by the shareholders' meeting on May 16, 2025, and approved by the board meeting on August 25, 2025 [2][3]. - The distribution is based on a total share capital of 108,220,000 shares [4]. - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3]. Implementation Details - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited [5]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the designated trading is completed [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of CNY 0.12 per share [9]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [9]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax will apply, resulting in a net distribution of CNY 0.108 per share [10]. - Hong Kong investors will also receive a net distribution of CNY 0.108 per share after a 10% withholding tax [11]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's board secretary office at 021-64959122 [12].

Group 1 - The company announced a cash dividend of 0.12 yuan per share (including tax) for the first half of 2025 [2] - The record date for the dividend is set for September 25, 2025 [2] - The ex-dividend date and the date of cash dividend distribution are both scheduled for September 26, 2025 [2]

证券代码：688163 证券简称：赛伦生物 公告编号：2025-027 上海赛伦生物技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/25 | 2025/9/26 | 2025/9/26 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东会授权董事会制 定，并经公司 2025 年 8 月 25 日召开的第四届董事会第八次会议审议通过后实施。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本108,220,000股为基数，每股派发现 金红利0.12元（含税），共 ...

Summary of Key Points Core Viewpoint - On September 11, a total of 9 companies had their restricted shares unlocked, with a total unlock volume of 114 million shares, amounting to a market value of 3.989 billion yuan based on the latest closing price [1]. Group 1: Unlock Volume - Two companies had unlock volumes exceeding 10 million shares: Sailun Biotech with 63.848 million shares and Qingmu Technology with 16.8263 million shares [1]. - The third company with significant unlock volume is Shida Group, which had 9.425 million shares unlocked [1]. Group 2: Unlock Market Value - Two companies had unlock market values exceeding 100 million yuan: Sailun Biotech with 1.567 billion yuan and Qingmu Technology with 1.119 billion yuan [1]. - The third company with a notable unlock market value is Huihan Co., which had an unlock market value of 685 million yuan [1]. Group 3: Unlock Ratio - Two companies had unlock ratios exceeding 10%: Sailun Biotech with 59.0% and Qingmu Technology with 18.18% [1]. - The third company with a significant unlock ratio is Haisheng Pharmaceutical, which had an unlock ratio of 7.38% [1].

Group 1 - The company has initiated two new drug research projects in the first half of 2025, focusing on broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulase, currently in the laboratory research phase [1] - The company's export of anti-snake venom serum raw liquid to South Korea is noted, with both the export business amount and its proportion in operating revenue being very small [1] - Specific data regarding overseas operating revenue can be referenced in the company's annual reports [1]

Summary of Key Points Core Viewpoint - On August 27, 2023, Siron Biotech's stock fell by 5.18%, with a trading volume of 89.71 million yuan, indicating a potential concern among investors regarding the company's performance and market sentiment [1]. Financing and Trading Data - On the same day, Siron Biotech had a financing buy amount of 8.79 million yuan and a financing repayment of 14.48 million yuan, resulting in a net financing buy of -5.68 million yuan [1]. - As of August 27, the total financing and securities lending balance for Siron Biotech was 152 million yuan, which represents 13.58% of its market capitalization [1]. - The financing balance is at a high level, exceeding the 90th percentile of the past year [1]. - There were no shares sold or repaid in the securities lending segment on August 27, indicating a lack of short-selling activity [1]. Company Overview - Siron Biotech, established on November 9, 1999, and listed on March 11, 2022, is based in Qingpu District, Shanghai [1]. - The company specializes in the research, development, production, and sales of preventive and therapeutic drugs related to biological toxins and biosafety [1]. - The main business revenue is derived entirely from antiserum and antitoxin products, accounting for 100% of its income [1]. Financial Performance - As of June 30, 2025, Siron Biotech reported a total of 7,724 shareholders, an increase of 9.39% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.58% to 5,744 shares [2]. - For the first half of 2025, the company achieved an operating income of 101 million yuan, reflecting a year-on-year growth of 2.82% [2]. - The net profit attributable to the parent company was 32.98 million yuan, also showing a year-on-year increase of 2.07% [2]. - Since its A-share listing, Siron Biotech has distributed a total of 235 million yuan in dividends, with 137 million yuan distributed over the past three years [2]. - Notably, as of June 30, 2025, a significant institutional shareholder, Southern Science and Technology Innovation Board 3-Year Open Mixed Fund, has exited the top ten circulating shareholders list [2].

Domestic News - A total of 40 listed companies in the A-share market will have their restricted shares unlocked next week, with a combined market value of approximately 966.01 billion yuan. The companies with the highest unlock values include Times Electric (278.23 billion yuan), Southern Power Storage (230.81 billion yuan), and BGI Genomics (133.82 billion yuan) [1] - The unlock ratios for several companies exceed 50%, with Minshida at 66.23%, Southern Power Storage at 65.3%, Sailun Biotech at 59%, and Zhejiang Hengwei at 50.95% [1] International News - The 24th Economic Ministers' Meeting of the Shanghai Cooperation Organization (SCO) was held in Vladivostok, Russia, focusing on sustainable economic growth measures and planning for future regional economic cooperation [2] - The price of domestic gold jewelry has surpassed 1,060 yuan per gram, with brands like Chow Sang Sang and Lao Miao reporting increases in their gold prices [3] - The completion of the first main tower of the Zhuhai Bridge, which connects Zhoushan's Liuhong Island and Foduo Island, marks a significant milestone in infrastructure development, with a main span of 1,768 meters [3]

Core Viewpoint - The A-share market will see a significant unlock of restricted shares, totaling approximately 966.01 billion yuan, with 40 stocks experiencing share unlocks next week [2]. Group 1: Stock Unlock Details - 40 stocks will have their restricted shares unlocked from September 8 to 12, with a total unlock market value of 966.01 billion yuan [2]. - Among these, 12 stocks have an unlock market value exceeding 10 billion yuan, with notable mentions including Times Electric (278.23 billion yuan), Southern Network Storage (230.81 billion yuan), and BGI Genomics (133.82 billion yuan) [2][4]. - Southern Network Storage and Western Gold are among the stocks with restricted shares unlocked from directed placements, while the other three are from the initial public offering (IPO) original shareholders [2]. Group 2: Unlock Proportions - A total of 13 stocks have an unlock proportion exceeding 10%, indicating a potential impact on their stock prices [5]. - Stocks such as Minshida, Southern Network Storage, Sairun Bio, and Zhejiang Hengwei have unlock proportions above 50% [5]. - The detailed table lists various stocks, their unlock dates, market values, and the proportion of shares being unlocked [7]. Group 3: Company Performance Insights - Times Electric's largest shareholder, CRRC Zhuzhou Electric Locomotive Research Institute, will unlock approximately 590 million shares, accounting for 43.42% of the total share capital [4]. - Times Electric reported a revenue of 12.214 billion yuan for the first half of 2025, reflecting a year-on-year growth of 17.95%, with a net profit of 1.672 billion yuan, up 12.93% [4]. - Minshida, listed on the Beijing Stock Exchange, achieved a revenue of 237 million yuan in the first half of 2025, marking a year-on-year increase of 27.91%, with a net profit of 63.03 million yuan, up 42.28% [8]. Group 4: Institutional Investment Insights - Institutions that participated in the directed placements of stocks like Western Gold and Southern Network Storage are expected to see positive returns from the unlocks, with Western Gold's return exceeding 180% and Southern Network Storage's over 70% [8]. - Among the 40 stocks, 15 are categorized as general equity incentive shares or restricted shares, with companies like Sany Heavy Energy and Zhaoyi Innovation having unlock market values exceeding 1 billion yuan [8].

Summary of Key Points Core Viewpoint - The A-share market will see a significant unlock of restricted shares next week, with a total market value exceeding 96 billion yuan, which may impact stock prices of the affected companies [2]. Group 1: Unlock Scale and Impact - A total of 40 stocks will have their restricted shares unlocked from September 8 to 12, with a combined market value of 966.01 billion yuan [2]. - Among these, 12 stocks have an unlock market value exceeding 1 billion yuan, with notable companies like Times Electric, Southern Power Storage, and BGI Genomics having unlock values of 278.23 billion yuan, 230.81 billion yuan, and 133.82 billion yuan respectively [2][4]. Group 2: Unlock Proportions - Thirteen stocks have an unlock ratio exceeding 10%, indicating a potentially significant impact on their stock prices. Companies such as Minshida, Southern Power Storage, and Sailun Bio have unlock ratios above 50% [5]. - The highest unlock ratio is seen in Minshida at 66.23%, followed by Southern Power Storage at 65.30% and Sailun Bio at 59.00% [7]. Group 3: Company Performance - Times Electric's major shareholder, CRRC Zhuzhou Electric Locomotive Research Institute, will unlock approximately 590 million shares, accounting for 43.42% of its total share capital. The company reported a revenue of 12.214 billion yuan for the first half of 2025, a year-on-year increase of 17.95%, and a net profit of 1.672 billion yuan, up 12.93% [4]. - Minshida, listed on the Beijing Stock Exchange, achieved a revenue of 237 million yuan in the first half of 2025, reflecting a year-on-year growth of 27.91%, with a net profit of 63.03 million yuan, up 42.28% [8]. Group 4: Institutional Investment Returns - Institutions that participated in the private placements of stocks like Western Gold and Southern Power Storage are expected to see positive returns from the unlock, with Western Gold's return exceeding 180% and Southern Power Storage's over 70% [8].

Core Viewpoint - Shanghai Sairun Biotechnology Co., Ltd. has completed the registration of business changes and obtained a new business license, reflecting significant corporate governance updates and operational scope adjustments [1][2]. Group 1: Corporate Changes - The company held board and supervisory meetings on July 24, 2025, to approve the cancellation of the supervisory board and changes to the business scope and articles of association [1]. - The company convened a temporary shareholders' meeting on August 11, 2025, to ratify the aforementioned changes [1]. - The updated business registration information includes a registered capital of RMB 108.22 million and a new operational scope that encompasses drug production, import/export, and various medical device services [2]. Group 2: Investor Communication - The company plans to participate in a collective performance briefing for the biotech and CXO industry from September 15, 2025, to discuss its semi-annual results and address investor inquiries [4][5]. - Investors can submit questions from September 8 to September 12, 2025, for discussion during the briefing [7]. - The briefing will be held online at the Shanghai Stock Exchange Roadshow Center, allowing for interactive communication with investors [6][8].